Analystreport

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating.

Aclaris Therapeutics, Inc.  (ACRS) 
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: aclaristx.com